Cochrane · systematic review · CD008900
Cerebrolysin for vascular dementia
Cui, S, Chen, N, Yang, M, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cerebrolysin for vascular dementia
Population: vascular dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (MMSE or ADAS‐cog+) | no estimate extracted | 3 studies · 420 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Quality of life | no estimate extracted | NR | No studies |
Caregiver burden | no estimate extracted | NR | No studies |
Binary outcomes | no estimate extracted | NR | No studies |
Improvement in cognitive function reported as responder rates (MMSE, ADAS‐cog+, and HDS) | no estimate extracted | 3 studies · 338 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Improvement in global function reported as response rates (CIBIC+ and CGI) | no estimate extracted | 2 studies · 379 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Non‐serious adverse events | no estimate extracted | 2 studies · 379 participants | Very low Downgraded: risk of bias, imprecision, indirectness |